JP2010540653A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540653A5
JP2010540653A5 JP2010528107A JP2010528107A JP2010540653A5 JP 2010540653 A5 JP2010540653 A5 JP 2010540653A5 JP 2010528107 A JP2010528107 A JP 2010528107A JP 2010528107 A JP2010528107 A JP 2010528107A JP 2010540653 A5 JP2010540653 A5 JP 2010540653A5
Authority
JP
Japan
Prior art keywords
nlrr
egfr
cancer
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528107A
Other languages
English (en)
Japanese (ja)
Other versions
JP5695905B2 (ja
JP2010540653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078474 external-priority patent/WO2009046123A2/en
Publication of JP2010540653A publication Critical patent/JP2010540653A/ja
Publication of JP2010540653A5 publication Critical patent/JP2010540653A5/ja
Application granted granted Critical
Publication of JP5695905B2 publication Critical patent/JP5695905B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528107A 2007-10-02 2008-10-01 Nlrr−1アンタゴニスト及びその使用 Expired - Fee Related JP5695905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97689207P 2007-10-02 2007-10-02
US60/976,892 2007-10-02
PCT/US2008/078474 WO2009046123A2 (en) 2007-10-02 2008-10-01 Nlrr-1 antagonists and uses thereof

Publications (3)

Publication Number Publication Date
JP2010540653A JP2010540653A (ja) 2010-12-24
JP2010540653A5 true JP2010540653A5 (https=) 2013-10-10
JP5695905B2 JP5695905B2 (ja) 2015-04-08

Family

ID=40526943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528107A Expired - Fee Related JP5695905B2 (ja) 2007-10-02 2008-10-01 Nlrr−1アンタゴニスト及びその使用

Country Status (7)

Country Link
US (1) US8691222B2 (https=)
EP (1) EP2207805B1 (https=)
JP (1) JP5695905B2 (https=)
AU (1) AU2008308761B2 (https=)
CA (1) CA2699601A1 (https=)
ES (1) ES2502217T3 (https=)
WO (1) WO2009046123A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124006A1 (en) * 2008-03-04 2011-05-26 Hismitsu Pharmaceutical Co., Inc. Method for screening of therapeutic agent for cancer
WO2019222506A1 (en) * 2018-05-16 2019-11-21 Chang Gung Memorial Hospital, Linkou Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof
US20240094187A1 (en) * 2020-12-30 2024-03-21 Beckman Coulter, Inc. Surface enhanced raman spectroscopic methods for detecting analytes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7265210B2 (en) * 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
WO2003104438A2 (en) * 2002-06-11 2003-12-18 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2006130135A1 (en) * 2005-05-31 2006-12-07 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20100028867A1 (en) * 2005-10-26 2010-02-04 Elizabeth Bosch LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer
US20080311107A1 (en) * 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

Similar Documents

Publication Publication Date Title
CN114206930B (zh) 针对抗cd73抗体和变体的方法和组合物
JP7256127B2 (ja) がんのための診断及び治療方法
US20090226455A1 (en) Combination therapy with c-met and her antagonists
US20160303127A1 (en) Combination therapy with c-met and egfr antagonists
CN102498129B (zh) 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
JP2019521641A (ja) がんを監視及び治療するための方法
CN102216331A (zh) 治疗方法
US20180282415A1 (en) Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
JP2012524083A (ja) アジュバント癌治療
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
JP5695905B2 (ja) Nlrr−1アンタゴニスト及びその使用
JP2010540653A5 (https=)
HK1146065B (en) Nlrr-1 antagonists and uses thereof
WO2011082187A1 (en) Methods for modulating a pdgf-aa mediated biological response
HK40113324A (zh) 针对抗cd73抗体和变体的方法和组合物
RU2825390C2 (ru) Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
HK40071709B (zh) 针对抗cd73抗体和变体的方法和组合物
HK40071709A (en) Method and composition for anti-cd73 antibodies and variants
HK40016679A (en) Therapeutic and diagnostic methods for cancer
AU2017202820A1 (en) Combination therapy with c-met and HER antagonists